http://rdf.ncbi.nlm.nih.gov/pubchem/reference/20033430

Outgoing Links

Predicate Object
contentType Comparative Study|Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, Non-U.S. Gov't
endingPage 45
issn 0098-7484
issueIdentifier 19
pageRange 2437-45
publicationName JAMA
startingPage 2437
bibliographicCitation Pedersen TR, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Holme I, Larsen ML, Bendiksen FS, Lindahl C, Szarek M, Tsai J; Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA. 2005 Nov 16;294(19):2437–45. doi: 10.1001/jama.294.19.2437. PMID: 16287954.
creator http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_ed1cba2c00a064fab2ab3031eb07382a
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f63bcad29a051c5fe8914275ffdc33ac
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_bbb7e4e003a25a55416cd28e57a7affd
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_073027d70e658cfe72e8f4b8783796c1
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_a71d89be80d250b3bef57009372ac29c
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_1f2d2592bfbc3df04f4df5b63bbf7e17
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e0b6f69f40450d1daeb2143ee76a4eeb
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_4eca1586d768006ce3a87a7e3bee29fd
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_4db6b80d8f2ef834375b92a61652e648
http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0002-0046-0264
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_995f30320533f70eaf70a2175241223f
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_61ca4823359602dfa5b7a9971eaf2f2b
date 2005-11-16-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier https://doi.org/10.1001/jama.294.19.2437
https://pubmed.ncbi.nlm.nih.gov/16287954
isPartOf http://rdf.ncbi.nlm.nih.gov/pubchem/journal/5346
https://portal.issn.org/resource/ISSN/0098-7484
language English
source https://pubmed.ncbi.nlm.nih.gov/
https://www.crossref.org/
title High-Dose Atorvastatin vs Usual-Dose Simvastatin for Secondary Prevention After Myocardial InfarctionThe IDEAL Study: A Randomized Controlled Trial
discusses http://id.nlm.nih.gov/mesh/M0010246
http://id.nlm.nih.gov/mesh/M0029425
http://id.nlm.nih.gov/mesh/M0012591
http://id.nlm.nih.gov/mesh/M0179294
http://id.nlm.nih.gov/mesh/M0028567
http://id.nlm.nih.gov/mesh/M0018276
discussesAsDerivedByTextMining http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5997
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8564
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9103
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8544
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7917
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID54454
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID60823
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7181
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7346

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID128121087
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID175427122
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129200050
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID46508654
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129742546
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID46508223
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID46506188

Total number of triples: 51.